Please assess the completion status of the following clinical trial:

Trial Title: Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* local advanced or metastatic non-small cell lung cancer~* large cell lung carcinoma or adenocinoma~* Previously treated by TKI-Chemotherapy or Chemotherapy-TKI~* EGFR T790M positive~* No uncontrolled hypertension~* No active bleeding or thrombosis in recent 6 months~* No previously treated with VEGF antibody~Exclusion Criteria:~* newly diagnosed thrombosis~* anti-coagulation therapy~* uncontrolled hypertension~* uncontrolled nephropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Docetaxel, bevacizumab (Type: ACTIVE_COMPARATOR): docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
- EGFR TKI (Type: EXPERIMENTAL): osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.

Based on this trial design, predict the completion outcome and termination type (if applicable).